Nanobac Life Sciences, Inc. Announces Baylor College of Medicine Initial Results for Nanoparticle and Gall Stone Formation Study
1/15/2008 9:08:35 AM
TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announces that scientists at the Baylor College of Medicine, working under a collaborative agreement with Nanobac, have cited evidence showing the presence of calcifying nanoparticles (CNPs) in surgically resected gallbladders with cholelithiasis (Gall Stones). This potentially represents a previously unrecognized factor in the development of cholecystitis and cholelithiasis disease.